Actively Recruiting
GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
Led by University of Kansas Medical Center · Updated on 2026-02-20
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how estrogen levels affect body composition and muscle function in midlife women who are taking a GLP-1 receptor agonist (GLP-1RA) medication for weight loss. The study focuses on women aged 35 to 60 who are newly prescribed this medication, aiming to understand how these factors change during treatment. The research is observational and sponsored by the University of Kansas Medical Center. Participants are new users of GLP-1RA medications and will undergo various measurements to assess body composition, hormone levels, muscle strength, and nutrition. These assessments will be conducted over a six-month period to observe changes while using the medication. The study does not introduce any experimental treatments but observes effects in natural settings. During the study, participants will have their body weight, body composition, bone mineral density, and muscle function evaluated from the start through the six-month visit. Researchers will also monitor estrogen levels and their role in changes to bone density and muscle function. Dietary intake and diet quality will be assessed as well. Participation involves regular evaluations to track these outcomes and understand the interaction between GLP-1RA therapy and estrogen in midlife women.
CONDITIONS
Brief Title
GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female
- Age between 35 and 60 years
- Body mass index (BMI) of 30 or higher, or BMI of 27 or higher with at least one cardiometabolic risk factor such as dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, or PCOS
- Newly prescribed a GLP-1RA medication
- English speaking
- Stable body weight for the past 6 months
You will not qualify if you...
- Pregnant women
- Under age 35 or over age 60
- Born male
- Unable to consent for themselves
- Cannot read or speak English
- Diagnosis of type 2 diabetes
- Recently stopped taking a GLP-1RA medication less than 6 months ago
- Contraindications for GLP-1RA medication including personal or family history of medullary thyroid carcinoma, family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, hypersensitivity to the drug, active suicidal thoughts
- Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants newly prescribed a GLP-1RA medication have measurements taken to assess body composition, hormone levels, muscle strength, and nutrition over time.
Baseline visit and follow-up visits through 6 months
Trial Site Locations
Total: 1 location
1
The University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Actively Recruiting
Research Team
J
Johanna Finkle, MD
H
Holly Hull, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here